The standard option for many patients with non-small cell lung cancer today is AstraZeneca’s targeted therapy Tagrisso. A year and a half ago, data showed this drug could provide patients with ...
Johnson & Johnson's Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
Hosted on MSN14d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
A better understanding of early childhood microbiome shifts offers a unique window for detecting disease risk and intervening appropriately. Experts from the Women’s Brain Foundation and bit.bio will ...
Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
Janssen looks for partnerships where the sum is greater than the parts—a synergistic focus that benefits both parties. As part of Johnson & Johnson, Janssen can leverage an array of resources to ...
Janssen-Cilag International NV, a Johnson & Johnson company, received European Medicines Agency's Committee for Medicinal Products ...
Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received a positive opinion from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback